High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma

Annals of Oncology

Volumn 16, Issue 3, 2005, Pages 445-449

  Jahnke, Kristoph ^a   Korfel, A ^a   Martus, P ^a   Weller, M ^b   Herrlinger, U ^b   Schmittel, A ^a   Fischer, L ^a   Thiel, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Elderly; Glomerular filtration rate; Methotrexate; Toxicity

Indexed keywords

CYTARABINE; DEXAMETHASONE; FOLINIC ACID; METHOTREXATE;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CALCULATION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ELDERLY CARE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; INFECTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 4 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 16244391825     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi075     Document Type: Article

References (13)

1. Plasswilm L, Herrlinger U, Korfel A et al. Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol 2002; 81: 415-423.
2. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group Experience. J Clin Oncol 2003; 21: 266-272.
3. O'Neill BP, O'Fallon JR, Earle JD et al. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995; 33: 663-673.
4. Blay JY, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864-871.
5. Thyss A, Milano G, Deville A et al. Effect of dose and repeat intravenous 24hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol 1987; 23: 843-847.
6. 2 methotrexate. Leuk Lymphoma 1994; 14: 141-144.
7. 2 in children with acute lymphoblastic leukemia. Cancer 1987; 60: 5-13.
8. Guha-Thakurta N, Damek D, Polack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma. Response to therapy and quality of life of patients. J Neurooncol 1999; 43: 259-268.
9. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO Offset Publications 1979.
10. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188-195.
11. Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21: 1044-1049.
12. Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multi-center trial of single-agent high-dose methotrexate for primary CNS lymphoma. Ann Neurol 2002; 51: 247-252.
13. Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neurooncol 2000; 2: 40-44.